Kawana T
Dept. of Obstetrics and Gynecology, Tokyo University Branch Hospital, Japan.
Gan To Kagaku Ryoho. 1995 May;22(6):711-7.
More than 13 years have passed since HPV DNA was first detected in cervical cancer. Vigorous studies, basic and clinical, during these years have elucidated the causative relationship of HPV with cervical cancer. There are more than seventy types of HPV, among which types 16, 58, 52, 18 and 31 were detected from cervical cancers obtained from Japanese women. HPV-DNA was detected from more than 90% of the cases of cervical dysplasia whose types were shown to be more widely distributed than those of cervical cancer. The serum antibody to HPV has been detected by Western blot or ELISA using fusion protein as antigen. Anti HPV-16/E7 antibody was detected in cervical cancer patients at significantly higher rates than in control patients. The expression of E6/E7 genes of high-risk HPVs (16, 18 and others) seems to be an essential but not a sufficient factor for malignant conversion of the cervical epithelium.
自首次在宫颈癌中检测到HPV DNA以来，已经过去了13年多。在这些年里，基础和临床方面都进行了大量研究，阐明了HPV与宫颈癌之间的因果关系。HPV有七十多种类型，其中16、58、52、18和31型是从日本女性宫颈癌中检测到的。在超过90%的宫颈发育异常病例中检测到了HPV-DNA，其类型分布比宫颈癌更为广泛。已通过使用融合蛋白作为抗原的蛋白质印迹法或ELISA检测到针对HPV的血清抗体。宫颈癌患者中检测到抗HPV-16/E7抗体的比例明显高于对照患者。高危型HPV（16、18等）的E6/E7基因表达似乎是宫颈上皮恶性转化的一个必要但不充分的因素。
